RxDoctor Payments Data

Jane Serio, MD

Internal Medicine · Manhasset, NYNPI 1730185679

Payments from drug & device makers

$5,229in general payments, 2019–2025

Across 251 payments — averaging $20.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$917
  • AstraZeneca$671
  • AbbVie$614
  • Novartis$345
  • GSK$329
  • Pfizer$296
  • plus $2K from 34 others

What the payments were for

  • Food & beverage$5,229100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,229 in reported general payments places this provider in the 85th percentile of 9,771 internal medicine providers in New York.

See all internal medicine providers in New York

Medicare billing

Part B allowed, 2024
$171,236
Medicare patients
566
Services billed
1,812

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide68$68,054
EliquisApixaban59$54,417
JanuviaSitagliptin Phosphate33$33,656
XareltoRivaroxaban26$22,712
JardianceEmpagliflozin24$21,081
MounjaroTirzepatide17$17,430
SynthroidLevothyroxine Sodium98$9,028
Trelegy ElliptaFluticasone/Umeclidin/Vilanter13$8,496
Breo ElliptaFluticasone/Vilanterol15$6,709
MyrbetriqMirabegron12$6,260
Stiolto RespimatTiotropium Br/Olodaterol Hcl11$5,251
Lantus SolostarInsulin Glargine,hum.Rec.Anlog24$4,509
Losartan Potassium334$3,913
Levothyroxine Sodium245$3,357
Albuterol Sulfate HfaAlbuterol Sulfate75$3,030

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$917$68,05468 claims
PfizerEliquis$296$54,41759 claims
MerckJanuvia$191$33,65633 claims
Boehringer IngelheimJardiance, Stiolto Respimat$182$26,33235 claims
Lilly USA, LLCMounjaro$117$17,43017 claims
GSKTrelegy Ellipta, Breo Ellipta$329$15,20628 claims
AbbVieSynthroid$614$9,02898 claims
Astellas Pharma US IncMyrbetriq$102$6,26012 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$17$3,357245 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 9,771 internal medicine providers in New York.

Other internal medicine in Manhasset

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →